Waltham, MA – According to filings with the U.S. Securities and Exchange Commission, Revere Pharmaceuticals is raising $3,487,668.00 in new funding. Sources indicate as part of senior management President, Robert Silverman played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Revere Pharmaceuticals

Revere Pharmaceuticals is an oncology focused biotechnology company leading the development of small molecule therapeutics targeting Rac1 signaling for cancers with unmet clinical need. Rac1 activity is a key driver of metastatic progression and drug resistance in diverse cancer types.

To learn more about Revere Pharmaceuticals, visit http://www.reverepharma.com/

Contact:
Robert Silverman, President
781-718-9033
https://www.linkedin.com/in/robert-silverman-467b236/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved